Dr Ryan O’Hare Doig, Head, Spinal Cord injury Research (SAHMRI)
Neil Sachse Centre for Spinal Cord Research (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA
Dr. Ryan O’Hare Doig’s early research career has focused on understanding the pathophysiology of secondary degeneration following neurotrauma to the central nervous system (CNS). He uses innovative analytical techniques to demonstrate biochemical, molecular and gross anatomical changes that occur following CNS injury. Dr. O’Hare Doig has developed and optimised a combinatorial treatment strategy incorporating pharmacotherapeutics for the treatment of CNS injury. Ryan’s combinatorial strategy has been assessed in a clinically relevant model of spinal cord injury (SCI), demonstrating significant functional recovery and tissue sparing, crucial for the translation of his research into clinical trials.
In 2017, Ryan joined the South Australian Health & Medical Research Institute (SAHMRI) and the Neil Sachse Centre for Spinal Cord Research, to provide his expertise in SCI and other neurotrauma models. Dr. O’Hare Doig’s lab looks to help develop new techniques to provide a more accurate diagnosis and prognosis of SCI, and to identify potential treatment strategies in a clinical setting.
You Might also like
-
Engineering bacteria to detect colorectal cancer cells
An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.
-
Dr Zarina Greenberg
RESEARCH IN SANFILIPPO
@ SAHMRI
ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA -
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.